Chemotherapy for the treatment of metastatic brain tumors

References

• Newton FIB. Neurological complications of systemic cancer. Am. Family Phys. 59, 878–886 (1999). A thorough clinical review.
   Google Scholar
• Newton HB. Primary brain tumors: review of etiology, diagnosis and treatment. Aim Family Phys. 49,787-797 (1994). A thorough clinical review.
   Google Scholar
• O'Neill BP, Buckner JC, Coffey RJ et al Brain metastatic lesions. Mayo Gun. Proc. 69,1062-1068 (1994). A thorough clinical review.
   Google Scholar
• Patchell RA. The treatment of brain metastases. Cancer Investig 14,169–177 (1996).
   PubMed Web of Science ®Google Scholar
• •Review of presentation and treatment.
   Google Scholar
• Wen PY, Loeffler JS. Management of brain metastases. Oncol 13,941–961 (1999).
   Google Scholar
• •Review of presentation and treatment.
   Google Scholar
• Farnell GF, Buckner JC, Cascino TL et al Brain metastases from colorectal carcinoma. The long-term survivors. Cancer78, 711–716 (1996).
   Google Scholar
• Sampson JH, Carter JH, Friedman AH, Seigler HE Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88,11-20 (1998).
   Google Scholar
• Leroux PD, Berger MS, Elliott JP, Tamimi HK. Cerebral metastases from ovarian carcinoma. Cancer67, 2194–2199 (1991).
   PubMed Web of Science ®Google Scholar
• Martinez-Manas RM, Brell M, Rumia J, Ferrer E. Case report. Brain metastases in endometrial carcinoma. Gyn. Oncol 70, 282–284 (1998).
   Google Scholar
• Mccutcheon IE, Eng DY, Logothetis CJ. Brain metastasis from prostate carcinoma. Antemortem recognition and outcome after treatment. Cancer 86,2301–2311 (1999).
   Google Scholar
• Lowis SP, Foot A, Gerrard MP et al Central nervous system metastasis in Wilms' tumor. A review of three consecutive United Kingdom trials. Cancer 83,2023–2029 (1998).
   Google Scholar
• Culine S, Bekradda M, Kramar A et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer83, 2548–2553 (1998).
   PubMed Web of Science ®Google Scholar
• Qasho R, Tommaso V, Rocchi G et al Choroid plexus metastasis from carcinoma of the bladder: case report and review of the literature. J. Neurooncol 45,237–240 (1999).
   PubMed Web of Science ®Google Scholar
• Salvati M, Frati A, Rocchi G et al Single brain metastasis from thyroid cancer: report of twelve cases and review of the literature. Neurooncol 51,33–40 (2001).
   PubMed Web of Science ®Google Scholar
• Ogawa K, Toita T, Sueyama H et al Brain metastases from esophageal carcinoma. Natural history, prognostic factors and outcome. Cancer94, 759–764 (2002).
   Google Scholar
• Espat NJ, Bilsky M, Lewis JJ et al Soft tissue sarcoma brain metastases. Prevalence in a cohort of 33829 patients. Cancer 94, 2706–2711 (2002).
   Google Scholar
• Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney and lung and melanoma. Cancer 94, 2698–2705 (2002).
   PubMed Web of Science ®Google Scholar
• Berk L. An overview of radiotherapy trials for the treatment of brain metastases. Oncol 9, 1205–1212 (1995).
   Google Scholar
• •Detailed review of radiotherapy trials for MBT.
   Google Scholar
• Lang FF, Sawaya R. Surgical management of cerebral metastases. Neurosurg. Clin. N Am 7, 459–484 (1996).
   PubMed Web of Science ®Google Scholar
• ••A thorough clinical review.
   Google Scholar
• Lesser GJ. Chemotherapy of cerebral metastases from solid tumors. Neurosurg. Clin. N. Am. 7, 527–536 (1996).
   PubMed Web of Science ®Google Scholar
• •Review of chemotherapy of solid tumors.
   Google Scholar
• Newton HB. Novel chemotherapeutic agents for the treatment of brain cancer. Expert Opin. Investig Drugs. 12, 2815–2829 (2000).
   Google Scholar
• ••A thorough pharmacological and therapeutic review.
   Google Scholar
• Liotta LA, Stetler-Stevenson WG, Steeg PS. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Investig 9, 543–551 (1991).
   PubMed Web of Science ®Google Scholar
• ••A detailed basic science review.
   Google Scholar
• Reilly JA, Fidler IJ. The biology of metastatis. Contemp Oncol 32–46 (1993).
   Google Scholar
• Aznavoorian S, Murphy AN, Stetler- Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 71, 1368–1383 (1993).
   Google Scholar
• ••A thorough review of molecular biology ofmetastasis
   Google Scholar
• Webb CP, Vande Woude GE Genes that regulate metastasis and angiogenesis. Neurooncol 50, 71–87 (2000).
   PubMed Web of Science ®Google Scholar
• ••Detailed review of the genetics ofmetastasis and angiogenesis.
   Google Scholar
• Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst. 92, 1717–1730 (2000).
   PubMedGoogle Scholar
• •Review of metastasis-suppressor genes.
   Google Scholar
• Hanahan D, Folkman J. Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. C1186, 353–364 (1996).
   Google Scholar
• ••A thorough review of angiogenesis.
   Google Scholar
• Beckner ME. Factors promoting tumor angiogenesis. Cancer Investig 17, 594–623 (1999).
   PubMed Web of Science ®Google Scholar
• •Review of angiogenic promoters.
   Google Scholar
• Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases J Neurooncol 44, 275–281 (1999).
   Google Scholar
• Gaspar L, Scott C, Rotman M et al Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int. J Rad OncolPhys 37, 745–751 (1997).
   PubMed Web of Science ®Google Scholar
• •Seminal RPA analysis of brain metastasis patients
   Google Scholar
• Nussbam ES, Djalilian HR, Cho KH, Hall WA. Brain metastases: histology, multiplicity, surgery and survival. Cancer 78, 1781–1788 (1996).
   PubMed Web of Science ®Google Scholar
• Twelves CJ, Souhami RL, Harper PG et al The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br. Cancer61, 147–150 (1990).
   Google Scholar
• Cocconi G, Lottici R, Bisagni G eta/. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Investig 8, 327–334 (1990).
   Google Scholar
• Franciosi V, Cocconi G, Michiara M et al Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small lung carcinoma, or melignant melanoma. A prospective study. Cancer 85, 1599–1605 (1999).
   Google Scholar
• Bernardo G, Cuzzoni Q, Strada MR et al First-line chemotherapy with vinorelbine, gemcitabine and carboplatin in the treatment of brain metastases from non-small cell lung cancer: a Phase II study. Cancer Investig 20, 293–302 (2002).
   PubMed Web of Science ®Google Scholar
• Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58, 832–839 (1986).
   Google Scholar
• Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer69, 972–980 (1992).
   Google Scholar
• Robinet G, Thomas P Breton JL et al Results of a Phase DI study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) protocol 95–101. Ann. Oncol 12, 59–67 (2001).
   Google Scholar
• Postmus PE, Haaxma-Reiche H, Smit EF et al Treatment of brain metastases of small cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy — c Phase DI study of the European Organization for the Research and Treatment of Cancer Lung Cancer Co-operative Group. J Clin. Oncol 18, 3400–3408 (2000).
   PubMed Web of Science ®Google Scholar
• Ushio Y, Arita N, Hayakawa T et al Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurg. 28, 201–205 (1991).
   PubMed Web of Science ®Google Scholar
• Newlands ES, Stevens MEG, Wedge SR et al Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Beat Rev 23, 35–61 (1997).
   Google Scholar
• ••A thorough review of pharmacology and early clinical trials.
   Google Scholar
• Hvisdos KM, Goa KL Temozolomide. CNS DITIF 12, 237–243 (1999).
   Web of Science ®Google Scholar
• •Review of pharmacology and clinical trials.
   Google Scholar
• Stupp RK, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet 017C0i 2, 552–560 (2001).
   Google Scholar
• ••A thorough review of pharmacology andearly clinical trials.
   Google Scholar
• Abrey LE, Olson JD, Raizer JJ et al A Phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J. Neurooncol 53, 259–265 (2001).
   PubMed Web of Science ®Google Scholar
• •Seminal Phase II trial of temozolomide for recurrent MBT.
   Google Scholar
• Christodoulou C, Bafaloukos D, Kosmidis P et al Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann. 017C0i 12, 249–254 (2001).
   Google Scholar
• Friedman H, Quinn J, Reardon D et al Phase II treatment of adults with brain metastases with Temodar. Neurooncol 3, 358 (2001) (Abstract).
   Google Scholar
• Dardoufas C, Miliadou A, Skarleas C et al Concomitant temozolomide (TMZ) and radiotherapy (RI) followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumours. Procee c I Ann. Soc. Clin. Oncol 20, 75b (2001) (Abstract).
   Google Scholar
• Antonadou D, Paraskaveides M, Coliarakis N et al. Temozolomide enhances radiation treatment efficacy in brain metastases: a randomized Phase II study. Proceed Ann. Soc. Clin. Oncol 20, 57a (2001) (Abstract) .
   Google Scholar
• Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. New Engl. J. Med. 345, 621–622 (2001).
   Google Scholar
• Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol 2, 634–635 (2001).
   PubMed Web of Science ®Google Scholar
• Stewart DJ. Pros and cons of intra-arterial chemotherapy. Oncol 3, 20–26 (1989).
   Google Scholar
• Yamada K, Bremer AM, West CR et al. Intra-arterial BCNU therapy in the treatment of metastatic brain tumor from lung carcinoma. A preliminary report. Cancer44, 2000–2007 (1979).
   Google Scholar
• Madajewicz S, West CR, Park HC et al Phase II study — intra-arterial BCNU therapy for metastatic brain tumors. Cancer 47, 653–657 (1981).
   PubMed Web of Science ®Google Scholar
• Cascino TL, Byrne TN, Deck MDF, Posner JB. Intra-arterial BCNU in the treatment of metastatic tumors. J. Neurooncol 1, 211–218 (1983).
   PubMedGoogle Scholar
• Madajewicz S, Chowhan N, Iliya A et al. Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer67, 2844–2849 (1991).
   PubMed Web of Science ®Google Scholar
• •An up-front IA treatment of MBT with objective responses.
   Google Scholar
• Barth RF, Yang W, Rotaru JH et al Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 57, 1129–1136 (1997).
   PubMed Web of Science ®Google Scholar
• Kroll RA, Neuwelt EA. Outwitting the blood—brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurg. 42, 1083–1100 (1998).
   PubMed Web of Science ®Google Scholar
• ••Detailed review of biology and therapeuticmanipulation of BBB.
   Google Scholar
• Eckman WW Pattack CS, Fenstermacher JD. A critical evaluation of the principles governing the advantages of IA infusion. J. Pharmacokinet. Biopharmacokinet 2, 257–285 (1974).
   PubMedGoogle Scholar
• Gelman M, Chakeres D, Newton FIB. Brain tumors: Complications of cerebral angiography accompanied by intra-arterial chemotherapy. Radial 213, 135–140 (1999).
   Google Scholar
• •Angiography with IA chemotherapy safe and well-tolerated.
   Google Scholar
• Newton FIB, Stevens C, Santi M. Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and iv. etoposide: a case report. I Neurooncol 55, 179–184 (2001).
   Google Scholar
• Newton FIB, Snyder MA, Stevens C et al. Intra-arterial carboplatin and iv. etoposide for the treatment of brain metastases. J. Neurooncol (In Press).
   Google Scholar
• Kroll RA, Pagel MA, Muldoon LL et al. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood—brain and/or blood—tumor barriers. Neurosurg. 43, 879–889 (1998).
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Dahlborg SA. Chemotherapy administered in conjunction with osmotic blood—brain barrier modification in patients with brain metastases. J Neurooncol 4, 195–207 (1987).
   PubMed Web of Science ®Google Scholar
• Doolittle ND, Miner ME, Hall WA et al. Safety and efficacy of a multicenter study using intra-arterial chemotherapy in conjunction with osmotic opening of the blood—brain barrier for the treatment of patients with malignant brain tumors. Cancer88, 637–647 (2000).
   PubMed Web of Science ®Google Scholar
• Tomita T Interstitial chemotherapy for brain tumors: review. J Neumoncol 10, 57–74 (1991).
   PubMed Web of Science ®Google Scholar
• •Review of the principles of interstitial chemotherapy.
   Google Scholar
• Brem H, Mahaley MS, Vick NA et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. I Neurosurg. 74, 441–446 (1991).
   PubMed Web of Science ®Google Scholar
• Tamargo RJ, Myseros JS, Epstein JI et al. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. 53, 329–333 (1993).
   PubMed Web of Science ®Google Scholar
• Brem H, Langer R. Polymer-based drug delivery to the brain. Science Med 3, 2–11 (1996).
   Google Scholar
• •A thorough review of pharmacology.
   Google Scholar
• Ewend MG, Anderson RC, Tabassi K et al. Local delivery of BCNU from biodegradable polymer is superior to radiation therapy in treating intracranial melanoma metastases. Surg. Forum. XLVII, 564–566 (1996).
   Google Scholar
• Ewend MG, Williams JA, Tabassi K et al Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res. 56, 5217–5223 (1996).
   PubMed Web of Science ®Google Scholar
• Ewend MG, Sampath P, Williams JA et al Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurg 43, 1185–1193 (1998).
   PubMed Web of Science ®Google Scholar
• Ewend MG, Brem S, Gilbert M et al. The treatment of single brain metastasis with surgery, BCNU-polymer wafers and radiation therapy: Results of a Phase I-II trial. Proc. Ann. Soc. Clin. Oncol. 20, 57a (2001) (Abstract).
   Google Scholar
• Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur. Cancer35, 2010–2030 (1999).
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of molecular-based drug design.
   Google Scholar
• Livitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782–1788 (1995).
   PubMed Web of Science ®Google Scholar
• Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. I Clin. Investig. 105, 9–13 (2000).
   PubMed Web of Science ®Google Scholar
• Dillman RO. Monoclonal antibodies in the treatment of malignancy: Basic concepts and recent developments. Cancer/nvestig. 19, 833–841 (2001).
   Google Scholar
• •Review of clinical application of monoclonal antibodies.
   Google Scholar
• Hao D, Rowinsky EK. Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and ras inhibitors. Cancer InvestrXr. 20, 387–404 (2002).
   PubMed Web of Science ®Google Scholar
• ••A detailed review of pharmacology andpreclinical data.
   Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther: 82, 241–250 (1999).
   PubMed Web of Science ®Google Scholar
• Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in honhuman cancers to therapeutic target in human neoplasia. I Clin. Oncol. 19, 32s-40s (2001).
   Google Scholar
• ••A thorough review of EGFR function andtherapeutic inhibition.
   Google Scholar
• Hidalgo M, Siu LL, Nemunaitis J et al Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. I Clin. amyl 19, 3267–3279 (2001).
   Google Scholar
• Giese NA, Lokker NA, Yu, JC et al Development of antagonists of the platelet-derived growth factor receptor family. Oncol Spectrums 2, 550–556 (2001).
   Google Scholar
• Rowinsky EK, Windle JJ, von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. I Clin. Oncol. 17, 3631–3652 (1999).
   Google Scholar
• ••A thorough review of Ras signaling andtherapeutic inhibition.
   Google Scholar
• Adjei AA. Blocking oncogenic ras signaling for cancer therapy. I Natl Cancer Inst. 93, 1062–1074 (2001).
   PubMed Web of Science ®Google Scholar
• Crul M, de Klerk GJ, Swart M et a/. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.' Clin. 017C0i 20, 2726–2735 (2002).
   Google Scholar
• Yip D, Ahmad A, Karapetis CS et al Matrix met alloprotease inhibitors: applications in oncology. Investig. New Drugs 17, 387–399 (1999).
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Edkhardt SG. Development of matrix met alloprotease inhibitors in cancer therapy. Natl Cancer Inst. 93, 178–193 (2001).
   Google Scholar
• ••A thorough review of matrixmet alloprotease inhibitors.
   Google Scholar
• Sampson JH, Grossi PM, Ocahai H et al Intracerebral microinfusion of Herceptin in an athymic rat model of intracranial metastatic breast cancer. Proc. Am Assoc. Cancer Res. 43, 924 (2002) (Abstract).
   Google Scholar
• Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. j Clin. Oncol. 20, 325–334 (2001).
   Google Scholar
• Savage DG, Antman DH. Imatinib mesylate — a new oral targeted therapy. New Engl. J. Med 346, 683–693 (2002). A thorough review of pharmacotherapeutics of imatinib mesylate.
   Google Scholar
• Heinhich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity; a novel molecular approach to the treatment of KIT-positive malignancies. Oncol. 20, 1692–1703 (2002).
   Google Scholar
• Brooks BJ, Bani JC, Fletcher CDM, Demeteri GD. Response of metastatic gastrointestinal Animal tumor including CNS involvement to imatinib mesylate (STI-571). J. Clin. Oncol. 20, 870–872 (2002).
   Google Scholar